4-(2-phenylhydrazinyl)-3-acetyl-6-methyl-2H-pyran-2-one | 1370350-13-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-phenylhydrazinyl)-3-acetyl-6-methyl-2H-pyran-2-one
• 英文别名: 3-Acetyl-6-methyl-4-(2-phenylhydrazinyl)pyran-2-one
• CAS: 1370350-13-2
• 化学式: C₁₄H₁₄N₂O₃
• 分子量: 258.277
• InChiKey: ISTSGWCCNRBFNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2-phenylhydrazinyl)-3-acetyl-6-methyl-2H-pyran-2-one 在 溶剂黄146 作用下， 生成 3,6-dimethyl-2-phenylpyrano<4,3-c>pyrazol-4(2H)-one
  参考文献：
  名称：

  Design, synthesis, computational and biological evaluation of some new hydrazino derivatives of DHA and pyranopyrazoles

  摘要：

  Two series of compounds namely, 4-aryl/heteroaryl hydrazino-3-acetyl-6-methyl-2H-pyran-2-ones (4a-4j) and pyrano[4,3-c]pyrazoles (6a-6e and 6g) were synthesized starting from 3-acetyl-4-chloro-6-methyl-2H-pyran-2-one (2). Estimation of pharmacotherapeutic potential, possible molecular mechanism of action, toxic/side effects and interaction with drug-metabolizing enzymes were made for the synthesized compounds on the basis of prediction of activity spectra for substances (PASS) prediction results and their analysis by PharmaExpert software. COX inhibition predicted by PASS was confirmed by experimental evaluation and validated via docking studies. Out of all the compounds, compounds 4h, 4j, 6e, 6g exhibited good anti-inflammatory activity, whereas compounds 4b, 4c, 4h, 4i, 4j, 6b, 6e, 6g showed excellent analgesic activity compared with standard drug Diclofenac sodium. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.01.042
• 作为产物：
  描述：

  去氢乙酸 在 五氯化磷 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 4-(2-phenylhydrazinyl)-3-acetyl-6-methyl-2H-pyran-2-one
  参考文献：
  名称：

  Design, synthesis, computational and biological evaluation of some new hydrazino derivatives of DHA and pyranopyrazoles

  摘要：

  Two series of compounds namely, 4-aryl/heteroaryl hydrazino-3-acetyl-6-methyl-2H-pyran-2-ones (4a-4j) and pyrano[4,3-c]pyrazoles (6a-6e and 6g) were synthesized starting from 3-acetyl-4-chloro-6-methyl-2H-pyran-2-one (2). Estimation of pharmacotherapeutic potential, possible molecular mechanism of action, toxic/side effects and interaction with drug-metabolizing enzymes were made for the synthesized compounds on the basis of prediction of activity spectra for substances (PASS) prediction results and their analysis by PharmaExpert software. COX inhibition predicted by PASS was confirmed by experimental evaluation and validated via docking studies. Out of all the compounds, compounds 4h, 4j, 6e, 6g exhibited good anti-inflammatory activity, whereas compounds 4b, 4c, 4h, 4i, 4j, 6b, 6e, 6g showed excellent analgesic activity compared with standard drug Diclofenac sodium. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.01.042

文献信息

• Design, synthesis, computational and biological evaluation of some new hydrazino derivatives of DHA and pyranopyrazoles
  作者：Ajay Kumar、Poonam Lohan、Deepak K. Aneja、Girish Kumar Gupta、Dhirender Kaushik、Om Prakash

  DOI：10.1016/j.ejmech.2012.01.042

  日期：2012.4

  Two series of compounds namely, 4-aryl/heteroaryl hydrazino-3-acetyl-6-methyl-2H-pyran-2-ones (4a-4j) and pyrano[4,3-c]pyrazoles (6a-6e and 6g) were synthesized starting from 3-acetyl-4-chloro-6-methyl-2H-pyran-2-one (2). Estimation of pharmacotherapeutic potential, possible molecular mechanism of action, toxic/side effects and interaction with drug-metabolizing enzymes were made for the synthesized compounds on the basis of prediction of activity spectra for substances (PASS) prediction results and their analysis by PharmaExpert software. COX inhibition predicted by PASS was confirmed by experimental evaluation and validated via docking studies. Out of all the compounds, compounds 4h, 4j, 6e, 6g exhibited good anti-inflammatory activity, whereas compounds 4b, 4c, 4h, 4i, 4j, 6b, 6e, 6g showed excellent analgesic activity compared with standard drug Diclofenac sodium. (C) 2012 Elsevier Masson SAS. All rights reserved.